We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

5 hedge funds and large institutions have $3.23K invested in Indaptus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.71% less ownership

Funds ownership: 4.76% → 0.05% (-4.7%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

71% less funds holding

Funds holding: 17 → 5 (-12)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 13

100% less capital inflows, than outflows

Capital inflows: $432 | Capital outflows: $374K

Holders
5
Holders Change
-12
Holders Change %
-70.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$315
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$117

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$141K
2
Investment House LLC
Investment House LLC
California
-$70.9K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$68.7K
4
Strategy Asset Managers
Strategy Asset Managers
California
-$24.9K
5
Pine Valley Investments
Pine Valley Investments
New Jersey
-$24.1K

INDP Hedge Fund Activity: Q2 2025 in Review

5 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2025, worth a combined $3.23K — down 99% from $378K a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of INDP and 1 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, adding an estimated $315. The largest seller was Vanguard Group, exiting entirely with an estimated $141K sold.

  • 5 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2025, down from 17 in Q1 2025.
  • Funds reported $3.23K of Indaptus Therapeutics stock for Q2 2025, down 99% quarter-over-quarter.
  • 1 fund opened new Indaptus Therapeutics positions in Q2 2025 and 13 closed out, a net change of -12 holders.
  • The largest Indaptus Therapeutics buyer in Q2 2025 was Bank of America, an estimated $315 added.
  • The largest Indaptus Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $141K sold.

Based on aggregated 13F filings for Q2 2025.